Efficacy of Janus kinase inhibitors investigated in randomised controlled trials published until March 2019
| Disease | Total | Tofacitinib (JAK 1–3) | Baricitinib (JAK 1/2) | Upadacitinib (JAK 1) | Filgotinib (JAK 1) | Decernotinib (JAK 3) | Peficitinib (JAK 1–3) | Others |
|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | 39 | 13 | 6 | 8 | 4 | 3 | 5 | 0 |
| Psoriatic arthritis | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Ankylosing spondylitis | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Systemic lupus erythematosus | 2 | 0 | 1 | 0 | 0 | 0 | 0 | Solcitinib (1) |
| Chronic plaque psoriasis | 10 | 6 | 1 | 0 | 0 | 0 | 1 | BMS-986 165 (1) Itacitinib (1) |
| Ulcerative colitis | 6 | 2 | 0 | 3 | 0 | 0 | 1 | 0 |
| Crohn’s disease | 5 | 2 | 0 | 2 | 1 | 0 | 0 | 0 |
| Alopecia areata/universalis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | PF-06651600 (1) |
| Atopic dermatitis | 4 | 1 | 1 | 1 | 0 | 0 | 0 | JTE-052 (1) |
| Total | 72 | 27 | 9 | 14 | 7 | 3 | 7 | 5 |
JAK, Janus kinase.